Dendreon Announces Webcast Presentation at ROTH Conference
25th Annual ROTH Conference
SEATTLE -- March 12, 2013
March 12, 2013—Dendreon Corporation (NASDAQ:DNDN) today announced that
management will present at the 25^th Annual ROTH Conference in Laguna Niguel,
California, on March 18, 2013, at 11:00 a.m. PT.
The presentation will be webcast live and available for replay from Dendreon's
website, www.dendreon.com. If you are unable to listen to the live webcast, it
will be archived on the site following the presentation. To access the replay,
go to the Investor Relations section of the website.
Dendreon Corporation is a biotechnology company whose mission is to target
cancer and transform lives through the discovery, development,
commercialization and manufacturing of novel therapeutics. The Company applies
its expertise in antigen identification, engineering and cell processing to
produce active cellular immunotherapy (ACI) product candidates designed to
stimulate an immune response in a variety of tumor types. Dendreon's first
product, PROVENGE^® (sipuleucel-T), was approved by the U.S. Food and Drug
Administration (FDA) in April 2010. Dendreon is exploring the application of
additional ACI product candidates and small molecules for the potential
treatment of a variety of cancers. The Company is headquartered in Seattle,
Washington, and is traded on the NASDAQ Global Market under the symbol DNDN.
For more information about the Company and its programs, visit
Lindsay Rocco, 862-596-1304
Nicole Soley, 206-455-2384
Press spacebar to pause and continue. Press esc to stop.